Spurious Prolongation of the Activated Partial Thromboplastin Time

Summary

The clinical and laboratory data of 8 patients (4 males and 4 females) with circulating anticoagulant were presented. Based on prolonged APTT, failure to correct the APTT with 50 % normal plasma and abnormal tissue thromboplastin inhibition test, the inhibitor was identified as “middle stage” – or the “lupus anticoagulant”. Thrombokinetics showed the maximal rate of change in optical density (V_maxΔOD) of plasma, resulting from clot formation to be significantly less in the plasma of patients with the inhibitor than in normal plasma. This was not completely corrected by mixing the patients’ plasma with 50% normal plasma.

• References

• 1 Abraham J. P, Ututin O. N, Johnson S. A, Caldwell J. 1961; A study of the defects in the blood coagulation mechanisms in polycythemia vera. American Journal of Clinical Pathology 36: 7.
• 2 Bowie E. W, Thompson J. Y, Cascuzzi P. A, Owen G. A. 1963; Thrombosis in SLE despite circulating anticoagulants. Journal of Laboratory and Clinical Medicine 62: 416.
• 3 Conley C. L, Hartmann R. C. 1952; A hemorrhagic disorder caused by circulating anticoagulants in patients with disseminated Lupus Erythematosus. Journal of Clinical Investigation 31: 621.
• 4 Donaldson V. H. et al. 1976; Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in the clotting and fibrinolysis. Journal of Laboratory and Clinical Medicine 87 (02) 327.
• 5 Feinstein D. J, Rapaport S. I. 1972; Acquired inhibitors of blood coagulation. Progressin Hemostasis and Thrombosis 1: 75.
• 6 Green D. 1972; Circulating anticoagulants. Medical Clinics of North America 56: 145.
• 7 Hathway W. E, Belhasen L. P, Hethnay H. S. 1965; Evidence for a new plasma thromboplastin I. Case Report. Coagulation Studies and Physicochemical Properties. Blood 26: 521.
• 8 Karaca M, Stefanini M. 1967; Thromboplastic activity and content in lipids and phospholipids of platelets in polycythemia vera with associated thrombocytopathy. American Journal of Clinical Pathology 48: 320.
• 9 Lechner K. 1974; Acquired inhibitors in non-hemophilic patients. Hemostasis 3: 65.
• 10 Lechner K. 1969; A new type of coagulation inhibitor. Thrombosis et Diathesis Haemorrhagica 21: 482.
• 11 Loeliger A. 1959; Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus. Thrombosis et Diathesis Haemorrhagica 3: 327.
• 12 Medal L. S, Lisker R. 1959; Circulating anticoagulants in disseminated Lupus Erythematosus. British Journal of Hematology 5: 284.
• 13 Natelson E. A, Dooley D. F. 1974; Rapid determination of fibrinogen by thrombokinetics. American Journal of Clinical Pathology 61: 628.
• 14 Natelson E. A, Shapiro D, Smith D. F. 1975; Detection of mild factor VIII deficiency by thrombokinetics. American Journal of Clinical Pathology 64: 95.
• 15 Rapaport S. L, Ames S. B, Duvall B. J. 1960; A plasma coagulation defect in Systemic Lupus Erythematosus arising from hypoprothrombinemia combined with anti-thrombinase activity. Blood 15: 212.
• 16 Ratnoff O. D, Colopy J. E. 1955; A familial hemorrhagic trait associated with a deficiency of a clotpromoting fraction of plasma. Journal of Clinical Investigation 34: 602.
• 17 Regan M. G. et al. 1974; Platelet function and coagulation profile in Lupus Erythematosus: Studies in 50 cases. Annals of Internal Medicine 81: 462.
• 18 Rivard A. E, Schiffman S, Rapaport S. I. 1974; Co-factor of the “Lupus Anticoagulants”. Thrombosis et Diathesis Haemorrhagica 32: 554.
• 19 Saito H, Ratnoff O. D, Waldmann R. et al. 1976; Fitzgerald trait. Journal of Clinical Investigation 55: 1082.
• 20 Schleider M. A. et al. 1976; Clinical study of the lupus anticoagulant. Blood 48: 499.
• 21 Yin E. T, Gaston L. W. 1965; Purification and kinetic studies on circulating anticoagulant in a suspected case of lupus erythematosus. Thrombosis et Diathesis Haemorrhagica 14: 88.